Amylyx (AMLX) announced that the FDA has granted fast track designation to AMX0114, an investigational antisense oligonucleotide targeting calpain-2 for the treatment of people living with amyotrophic lateral sclerosis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx initiated with a Buy at TD Cowen
- Amylyx price target raised to $8 from $7 at Mizuho
- Positive Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising HELIOS Trial Results for AMX0035
- Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges
- Amylyx announces results from Phase 2 HELIOS trial of AMX0035